Genta's oblimersen [Genasense] has received orphan drug designation for use in patients with stage IV malignant melanoma in Australia

Source: Inpharma, Volume 1, Number 1561, 2006-10-28 , pp. 23-23(1)

Publisher: Adis International

Keywords: Development-status; Malignant-melanoma, treatment; Oblimersen, therapeutic use; Orphan-drugs; Research-and-development

Document Type: Short communication

Publication date: 2006-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers